Bristol Historical Income Statement
BMY Stock | USD 48.99 0.15 0.31% |
Historical analysis of Bristol Myers income statement accounts such as Interest Expense of 1.2 B, Selling General Administrative of 3.6 B or Total Revenue of 47.3 B can show how well Bristol Myers Squibb performed in making a profits. Evaluating Bristol Myers income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Bristol Myers's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Bristol Myers Squibb latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bristol Myers Squibb is a good buy for the upcoming year.
Bristol |
About Bristol Income Statement Analysis
Bristol Myers Squibb Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Bristol Myers shareholders. The income statement also shows Bristol investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Bristol Myers Income Statement Chart
Bristol Myers Squibb Income Statement is one of the three primary financial statements used for reporting Bristol's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Bristol Myers Squibb revenue and expense. Bristol Myers Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Bristol Myers' Research Development is fairly stable compared to the past year. Net Income Applicable To Common Shares is likely to rise to about 6 B in 2024, whereas Selling General Administrative is likely to drop slightly above 3.6 B in 2024. Add Fundamental
Total Revenue
Total revenue comprises all receipts Bristol Myers Squibb generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Bristol Myers Squibb minus its cost of goods sold. It is profit before Bristol Myers operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Bristol Myers Squibb. It is also known as Bristol Myers overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Bristol Myers' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Bristol Myers Squibb current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At this time, Bristol Myers' Research Development is fairly stable compared to the past year. Net Income Applicable To Common Shares is likely to rise to about 6 B in 2024, whereas Selling General Administrative is likely to drop slightly above 3.6 B in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 36.4B | 36.0B | 34.3B | 36.0B | Total Revenue | 46.4B | 46.2B | 45.0B | 47.3B |
Bristol Myers income statement Correlations
Click cells to compare fundamentals
Bristol Myers Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bristol Myers income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 1.1B | 9.7B | 10.0B | 9.6B | 9.8B | 10.2B | |
Interest Expense | 656M | 1.4B | 1.3B | 1.2B | 1.2B | 1.2B | |
Selling General Administrative | 4.9B | 7.7B | 7.7B | 7.8B | 6.4B | 3.6B | |
Total Revenue | 26.1B | 42.5B | 46.4B | 46.2B | 45.0B | 47.3B | |
Gross Profit | 18.1B | 30.7B | 36.4B | 36.0B | 34.3B | 36.0B | |
Other Operating Expenses | 20.2B | 40.3B | 37.8B | 37.1B | 36.8B | 38.7B | |
Operating Income | 5.5B | 5.1B | 10.2B | 10.3B | 17.2B | 18.1B | |
Ebit | 5.5B | 5.1B | 10.2B | 10.3B | 9.4B | 5.1B | |
Ebitda | 6.6B | 14.8B | 20.2B | 19.9B | 19.2B | 20.1B | |
Cost Of Revenue | 8.1B | 11.8B | 9.9B | 10.1B | 10.7B | 5.8B | |
Total Operating Expenses | 12.2B | 28.6B | 27.9B | 26.9B | 26.1B | 27.4B | |
Income Before Tax | 5.0B | (6.9B) | 8.1B | 7.7B | 8.4B | 4.2B | |
Total Other Income Expense Net | (489M) | (12.0B) | (2.1B) | (2.6B) | 1.4B | 1.5B | |
Net Income | 3.4B | (9.0B) | 7.0B | 6.3B | 8.0B | 8.4B | |
Income Tax Expense | 1.5B | 2.1B | 1.1B | 1.4B | 400M | 380M | |
Research Development | 6.1B | 11.1B | 10.2B | 9.5B | 9.3B | 9.8B | |
Selling And Marketing Expenses | 4.9B | 7.7B | 7.7B | 7.8B | 1.4B | 1.3B | |
Net Income Applicable To Common Shares | 3.4B | (9.0B) | 7.0B | 6.3B | 5.7B | 6.0B | |
Minority Interest | 21M | 20M | (20M) | (18M) | (16.2M) | (15.4M) | |
Net Income From Continuing Ops | 6.5B | (9.0B) | 7.0B | 6.3B | 8.3B | 8.7B | |
Non Operating Income Net Other | (938M) | 2.3B | 720M | (576M) | (662.4M) | (629.3M) | |
Tax Provision | 1.5B | 2.1B | 1.1B | 1.4B | 322M | 305.9M | |
Net Interest Income | (656M) | (1.4B) | (1.3B) | (1.2B) | (1.1B) | (1.2B) | |
Interest Income | 69M | 71M | 550M | 1.9B | 2.1B | 2.2B | |
Reconciled Depreciation | 1.7B | 10.4B | 10.0B | 9.6B | 9.8B | 6.8B |
Pair Trading with Bristol Myers
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.Moving together with Bristol Stock
0.79 | A | Agilent Technologies Earnings Call This Week | PairCorr |
Moving against Bristol Stock
0.47 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Bristol Stock analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
CEOs Directory Screen CEOs from public companies around the world | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.09) | Dividend Share 2.31 | Earnings Share 3.86 | Revenue Per Share 21.753 | Quarterly Revenue Growth 0.006 |
The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.